Evidence map›Paper›PMID 41691507›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Liposomal Nanoconfinement Enables Type I Photodynamic Conversion for Synergistic Cancer Photothermal-Immunotherapy.

Minglu Zhang, Shanshan Liang, Meng Wang, Tingfeng Zhang, Jinke Liu, Yuyuan Peng, Hao Fang, Lingna Zheng, Xiao He, Meng Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Minglu ZhangQingdao Central Hospital, NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, Industry-Academia-Research Collaborative and Innovation Center For Intelligent Rehabilitation Drug R&D of Shandong Province, Qingdao Key Laboratory of Precision Drug Research for Chronic Disease Rehabilitation, School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Shanshan LiangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Meng WangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Tingfeng ZhangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Jinke LiuCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Yuyuan PengCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Hao FangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Lingna ZhengCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Xiao HeCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Meng WangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Luling WuState Key Laboratory of Analytical Chemistry For Life Science, School of Chemistry, Nanjing University, Nanjing, China.
Tony D JamesDepartment of Chemistry, University of Bath, Bath, BA27AY, UK.
Wei ZhaoQingdao Central Hospital, NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, Industry-Academia-Research Collaborative and Innovation Center For Intelligent Rehabilitation Drug R&D of Shandong Province, Qingdao Key Laboratory of Precision Drug Research for Chronic Disease Rehabilitation, School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Bing WangCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0000-0003-1632-3114
Weiyue FengCAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.

Funding

Beijing Natural Science Foundation Z230008Chinese Academy of Sciences E4545CU210National Key R&D Program of China 2022YFA1207600National Natural Science Foundation of China 12275300National Natural Science Foundation of China 12275302National Natural Science Foundation of China 12535020National Natural Science Foundation of China 32570817Scientific and Technological Innovation project of Institute of High Energy Physics
6 · The paper itself

Abstract

Type-I photodynamic therapy (PDT) agents offer a promising approach for treating hypoxic tumors. However, previous reports mainly focused on thermodynamic modulation through molecular engineering to block the Type-II energy transfer pathway. Herein, we present a facile strategy to realize the conversion of Type II to Type I PDT by integrating liposomal confinement and electron/hydrogen transfer pathway. A multifunctional nanoplatform, RhM-R837@Lip was developed, which facilitates an efficient shift from Type II to Type I for hemicyanine-based photosensitizer (PS) by suppressing singlet oxygen (

Indexed as

ImmunotherapyLiposomesNeoplasmsPhotochemotherapyPhotosensitizing AgentsPhotothermal TherapyAnimalsCell Line, TumorHumansMiceLiposomesPhotosensitizing Agentselectron transfernanoconfinementphotoimmunotherapyphotothermal therapytype I photodynamic therapy

Identifiers

PMID41691507
PMCPMC13104119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.